(NASDAQ: AVTX) Avalo Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.25%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 17.61%.
Avalo Therapeutics's earnings in 2024 is -$36,223,000.On average, 1 Wall Street analyst forecast AVTX's earnings for 2024 to be -$8,045,531, with the lowest AVTX earnings forecast at -$8,045,531, and the highest AVTX earnings forecast at -$8,045,531. On average, 1 Wall Street analyst forecast AVTX's earnings for 2025 to be -$6,783,893, with the lowest AVTX earnings forecast at -$6,783,893, and the highest AVTX earnings forecast at -$6,783,893.
In 2026, AVTX is forecast to generate -$1,571,878 in earnings, with the lowest earnings forecast at -$1,571,878 and the highest earnings forecast at -$1,571,878.